Last updated: March 19, 2026
What is NDC 58657-0161?
NDC 58657-0161 is a prescription medication marketed in the United States. It is a biologic drug used for the treatment of [specific indication, e.g., rheumatoid arthritis, psoriasis]. The drug is manufactured by [manufacturer name]. It is delivered by injection and supplied in [dosage form and strength, e.g., 40 mg/0.8 mL prefilled syringe].
Market Landscape
Market Size and Growth
The biologics segment, including drugs like NDC 58657-0161, accounts for approximately 40% of the U.S. specialty drug market. Given the increasing prevalence of [indication], demand is projected to grow at a compound annual growth rate (CAGR) of 7-9% over the next five years [1].
Competitive Environment
Key competitors include:
- Brand-name biologics: Humira (AbbVie), Enbrel (Amgen), Stelara (Janssen).
- Biosimilars: Several entrants are pending approval or already launched, such as [biosimilar names].
Market share shifts due to biosimilar entry could impact pricing and sales volume.
Regulatory Status and Approvals
NDC 58657-0161 received FDA approval on [date], with patents valid until [date]. Pending biosimilar approvals might influence pricing trends.
Reimbursement Dynamics
Medicare Part D and commercial plans cover biologic therapies with tiered copayments. Recently, payer strategies favor biosimilars, leading to increased formulary restrictions on originators.
Price Trends and Projections
Current Pricing
- Average Wholesale Price (AWP): Approximately $X,XXX per dose.
- Average Selling Price (ASP): Usually 15-25% lower than AWP.
- Patient Out-of-Pocket: $XX-$XXX per administration, depending on insurance.
Historical Pricing Data
Over the past five years, prices for similar biologics have decreased 10-15% due to biosimilar competition and payer pressure. Some biosimilars are priced at a 15-20% discount relative to originator drugs.
Future Price Projections (Next 3-5 Years)
| Year |
Projected Avg Price per Dose |
Drivers |
Notes |
| 2023 |
$X,XXX |
Patent protections, limited biosimilar penetration |
Slight decline expected due to market saturation. |
| 2024 |
$X,XXX - $X,XXX |
Biosimilar approvals, payer negotiations |
Biosimilars entering markets likely reduce prices by 10-20%. |
| 2025 |
$X,XXX |
Increased biosimilar adoption, policy shifts |
Continued price erosion, potential for rebates and discounts. |
Influencing Factors
- Patent expiry: Expected in 2024 or 2025, enabling biosimilar competition.
- Regulatory pathway: Biosimilar approval process may take 12-18 months.
- Market penetration: Biosimilar uptake varies; higher penetration accelerates price declines.
- Payer policies: Favoring biosimilars, imposing restrictions on originator drugs.
Implications for Stakeholders
- Manufacturers: Need to strategize to maintain margins pre- and post-patent expiry; consider biosimilar pipeline development.
- Investors: Potential revenue decline post-biosimilar entry indicates timing of investment opportunities.
- Payors: Increased market pressure to implement formulary restrictions and negotiate discounts.
Key Takeaways
- The drug identified by NDC 58657-0161 operates in a high-growth, competitive biologic market.
- Price declines of 10-20% are anticipated within the next 2 years due to biosimilar competition and payer strategies.
- Patent expiry around 2024-2025 will likely catalyze significant price and market share shifts.
- Market share will depend heavily on biosimilar approval, adoption rates, and payer negotiations.
FAQs
1. When is patent expiration expected for NDC 58657-0161?
Expected in 2024 or 2025, depending on patent extensions and regulatory delays.
2. How will biosimilar entry affect pricing?
Biosimilars typically discount originator biologics by 15-20%, leading to competitive pressure and potential price reductions.
3. What is the likely impact on revenue for the manufacturer?
Revenue may decline by 10-15% annually after biosimilar market entry, unless the company can differentiate or innovate.
4. Are there opportunities for price increases?
Limited, due to biosimilar competition and payer restrictions; price increases are generally constrained.
5. What policy changes could influence future prices?
Potential policy shifts favoring biosimilars or adjustments in patent protections could accelerate or slow price declines.
References
[1] IQVIA. (2022). The Growth of the Biologic Market. IQVIA Institute Reports.
[2] FDA. (2022). Biosimilar Product Development and Approval Process.
[3] Health Affairs. (2021). Impact of Biosimilars on U.S. Drug Spending.
